Raissa Munderere
Ph.D. Student

Department of Biomedical Engineering

Email: raissa.munderere@mail.mcgill.ca

LinkedIn | Scholar | ResearchGate

Educational Background:

Bachelor of Biomedical Engineering, Department of Biomedical Engineering - Pukyong National University (2022)

Master of Science, Department of Biomedical Engineering - Pukyong National University ( 2024)

Favourite Lab Equipment:

High speed Centrifuge <LABOGENE 2236r>

Curiosity is a strong cross-linker between Now and what we are meant to Do/who we are meant to Be
— Raissa Munderere

Research Project and Interests:

Diabetes is a chronic disorder with rapidly increasing prevalence that is a major global issue of our current era. There are no permanent therapeutic approaches for diabetes, and current therapies rely on regular administration of various drugs or insulin injection. There are two major types of diabetes: type 1 diabetes (T1D) and type 2 diabetes (T2D). Specifically, T1D etiology is multifaceted, involving a complex interplay of genetic predispositions and environmental factors, and is believed to arise as the consequence of selective autoimmune destruction of insulin-producing beta cells (β-cells) mediated by autoreactive CD4+ and CD8+ T lymphocytes (T cells). Currently, there is no cure for T1D, even though it is a very prevalent disease. Gene editing is a new technology that could provide promise and more permanent solutions to T1D patients. Targeted genome editing is a fast-growing technology, recruiting programmable nucleases to specifically modify target genomic sequences. These targeted nucleases generate double-strand breaks at target regions in the genome, which induce cellular repair pathways including non-homologous end joining (NHEJ) and homology-directed repair (HDR). CRISPR-associated protein 9 (Cas9) , clustered regularly interspaced palindromic repeats, is a novel gene-editing system, permitting precise genome modification. CRISPR/Cas9 has great potential for various applications in diabetic research, such as gene therapy, generation of diabetic animal models, and gene screening.